Phase I trial of GBR 500.
Phase of Trial: Phase I
Latest Information Update: 16 May 2011
At a glance
- Drugs Vatelizumab (Primary)
- Indications Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Multiple sclerosis
- Focus Adverse reactions
- Sponsors Glenmark Pharmaceuticals Ltd
- 18 Sep 2008 New trial record.
- 11 Sep 2008 IND submitted to the US FDA.